Aurora Cannabis Full Year 2025 Earnings: EPS Misses Expectations

Aurora Cannabis (TSE:ACB) Full Year 2025 Results

Key Financial Results

• Revenue: CA$343.3m (up 27% from FY 2024).
• Net income: CA$16.4m (up from CA$55.3m loss in FY 2024).
• Profit margin: 4.8% (up from net loss in FY 2024).
• EPS: CA$0.30 (up from CA$1.28 loss in FY 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aurora Cannabis EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 89%.

Looking ahead, revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada.

Performance of the Canadian Pharmaceuticals industry.

The company's shares are down 22% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Aurora Cannabis' balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.